Background and purpose: Trial discontinuation and non-publication represent major sources of research waste in clinical medicine. No previous studies have investigated non-dissemination bias in clinical trials of neurodegenerative diseases. Methods: ClinicalTrials.gov was searched for all randomized, interventional, phase II-IV trials that were registered between 1 January 2000 and 31 December 2009 and included adults with Alzheimer's disease, motor neurone disease, multiple sclerosis or Parkinson's disease. Publications from these trials were identified by extensive online searching and contact with authors, and multiple logistic regression analysis was performed to identify characteristics associated with trial discontinuation and non-publication. Results: In all, 362 eligible trials were identified, of which 12% (42/362) were discontinued. 28% (91/320) of completed trials remained unpublished after 5 years. Trial discontinuation was independently associated with number of patients (P = 0.015; more likely in trials with ≤100 patients; odds ratio 2.65, 95% confidence interval 1.21-5.78) and phase of trial (P = 0.009; more likely in phase IV than phase III trials; odds ratio 3.90, 95% confidence interval 1.41-10.83). Trial non-publication was independently associated with blinding status (P = 0.005; more likely in single-blind than double-blind trials; odds ratio 5.63, 95% confidence interval 1.70-18.71), number of centres (P = 0.010; more likely in single-centre than multi-centre trials; odds ratio 2.49, 95% confidence interval 1.25-4.99), phase of trial (P = 0.041; more likely in phase II than phase IV trials; odds ratio 2.88, 95% confidence interval 1.04-7.93) and sponsor category (P = 0.001; more likely in industry-sponsored than university-sponsored trials; odds ratio 5.05, 95% confidence interval 1.87-13.63). Conclusions: There is evidence of non-dissemination bias in randomized trials of interventions for neurodegenerative diseases. Associations with trial discontinuation and non-publication were similar to findings in other diseases. These biases may distort the therapeutic information available to inform clinical practice.
Introduction
Trial discontinuation and non-publication represent major sources of research waste in clinical medicine. Publicly available registers of trials have been established in the hope that increased transparency surrounding trial registration will lead to fewer being . CONSORT guidelines similarly state that registration numbers must be reported when publishing randomized trials [2] . In the USA, registration on ClinicalTrials.gov -the online database run by the National Library of Medicine À is mandatory for trials involving drugs or devices subject to Food and Drug Administration regulation [3] . Despite these stipulations, up to half of registered trials never result in a publication [4] .
No previous studies have investigated the factors influencing trial discontinuation and non-publication (non-dissemination bias) in clinical trials of neurodegenerative diseases. This is important given the increasing prevalence of these disorders within our ageing population and the need for symptomatic and disease-modifying therapies that will require testing in randomized trials.
The characteristics associated with trial discontinuation and non-publication in four major neurodegenerative diseases (Alzheimer's disease, motor neurone disease, multiple sclerosis and Parkinson's disease) were investigated by performing a cross-sectional analysis of the ClinicalTrials.gov database.
Methods
ClinicalTrials.gov search strategy TCHL and NES searched ClinicalTrials.gov using its Advanced Search facility with the following keywords: 'Alzheimer'; 'motor neuron OR amyotrophic lateral sclerosis'; 'multiple sclerosis'; and 'Parkinson'. Two authors (TCHL/NES and JDS) independently reviewed all trial entries and decided which met inclusion criteria. The following inclusion criteria were specified a priori: interventional trials; randomized trials with at least one comparator group; phase II, III or IV trials; trials involving adults and seniors; and trials registered between 1 January 2000 and 31 December 2009. There were no restrictions in terms of language, blinding status or methodological quality. Trials of several conditions were included if the neurodegenerative disease of interest was one of the conditions. Purely observational studies, trials of children only, or trials listed as 'unknown'/'enrolling by invitation' were excluded.
The following variables were extracted from each trial's database entry: disease, trial status, blinding status, number of centres, number of patients, phase of trial, sponsor category and type of intervention.
'Terminated', 'withdrawn' or 'suspended' trials were considered to be discontinued. 'Phase II/III' trials were considered as phase III. 'Industry' was defined as any commercial source; 'healthcare organization' as any organization directly providing clinical care; and 'funding organization' as any funding body outside of industry that was not a university or healthcare organization. 'Non-pharmacological' interventions were classed as devices, changes to participants' behaviour, or procedures. Cases of disagreement in category selection were resolved by consensus with the senior author (DPB).
Publication search strategy
'Publications' were defined as peer-reviewed journal articles containing outcome data. If a link to an included publication was not present on ClinicalTrials.gov, PubMed was searched using National Clinical Trial (NCT) number, trial name, author names and keywords. Publications that did not explicitly state the NCT number were discussed with the senior author before deciding whether they corresponded to the particular ClinicalTrials.gov trial, using the trial variables listed above to guide such decisions. If multiple publications were identified, the earliest date was used. If no publication was found for a completed trial, the author (defined as the investigator, sponsor or collaborator listed on ClinicalTrials.gov) was emailed to ask whether the trial had been published, and was sent a repeat email after 1 week if no reply was received. E-mail addresses were found from ClinicalTrials.gov or online searching.
Statistical analysis
SPSS version 23 (IBM Corp, Armonk, NY, USA) was used to perform bivariate analysis for each trial characteristic using chi-squared testing or, if <5 trials per category, Fisher's exact test to investigate whether these differed in discontinued or unpublished trials. Statistical significance was defined as P < 0.05 with Bonferroni correction. The post hoc z-test of two proportions was performed if a statistically significant trial characteristic had more than two categories. Variables with the greatest statistical significance on bivariate analysis were included in multiple logistic regression analysis, but the number of variables was limited to ensure an 'events per predictive variable ratio' of at least 10. The following characteristics were included as independent variables in multiple logistic regression against trial discontinuation: blinding status, number of patients and phase of trial. The following characteristics were included as independent variables in multiple logistic regression against trial non-publication: disease, blinding status, number of centres, number of patients, phase of trial, sponsor category and type of intervention. The reference category for multiple logistic regression analysis was chosen as the category with the lowest rate of trial discontinuation or non-publication on bivariate analysis. Trials with missing data were not included in the relevant bivariate or multivariate analyses.
Institutional review board approval, informed consent and trial registration
No ethical approval, patient consent or trial registration was required.
Results
Of the 2072 trials identified by ClinicalTrials.gov involving any of the neurodegenerative diseases of interest, 1710 were excluded and 362 were included in our analysis (Fig. 1) . 12% (42/362) of included trials were discontinued; most commonly reported reasons were recruitment difficulties (31%, 13/42) and lack of efficacy (14%, 6/42). After e-mailing study authors for clarification, 72% (229/320) of completed trials were found to have been published.
Trial characteristics associated with discontinuation on bivariate analyses (Table 1) were number of patients [P = 0.002; more discontinuation in trials with ≤100 patients (16.8%, 29/173) compared to >100 patients (6.2%, 11/176)] and phase of trial [P = 0.001; more discontinuation in phase IV trials (25.0%, 14/ 56) compared to phase II (11.6%, 21/181) or phase III (5.6%, 7/125) trials]. No other statistically significant associations were found. 13/42 (31%) discontinued trials did not report a reason for discontinuation, and phase IV trials (7.1%, 1/14) were less likely than phase III trials (57.1%, 4/7) to cite 'lack of efficacy' as a reason for discontinuation (P = 0.005). The three most significant variables on bivariate analyses (phase of trial, number of patients and blinding status) were used as independent variables in multiple logistic regression analysis (with trial discontinuation as the dependent variable). Number of patients (P = 0.015; discontinuation more likely in trials with ≤100 patients than >100 patients; odds ratio 2.65, 95% confidence interval 1.21-5.78) and phase of trial (P = 0.009; discontinuation more likely in phase IV than phase III trials; odds ratio 3.90, 95% confidence interval 1.41-10.83) were independently associated with discontinuation (Table 1) .
Trial characteristics associated with non-publication on bivariate analyses (Table 1) were number of centres [P = 0.004; more non-publication in single-centre trials (37.4%, 40/107) compared to multi-centre trials (22.1%, 45/204)], number of patients [P = 0.008; more non-publication in trials with ≤100 patients (36.1%, 52/144) compared to >100 patients (21.8%, 36/165)] and phase of trial [P = 0.001; more non-publication in phase II trials (37.5%, 60/160) compared to phase III (20.3%, 24/118) or phase IV (16.7%, 7/42) trials]. No other statistically significant associations were found. Multiple logistic regression included all variables from bivariate analyses (with trial non-publication as the dependent variable). Blinding status (P = 0.005; nonpublication rate higher in single-blind than doubleblind trials; odds ratio 5.63, 95% confidence interval 1.70-18.71), number of centres (P = 0.010; non-publication rate higher in single-centre than multi-centre trials; odds ratio 2.49, 95% confidence interval 1.25-4.99), phase of trial (P = 0.041; non-publication rate higher in phase II than phase IV trials; odds ratio 2.88, 95% confidence interval 1.04-7.93) and sponsor category (P = 0.001; non-publication rate higher in industry-sponsored than university-sponsored trials; odds ratio 5.05, 95% confidence interval 1.87-13.63) were independently associated with non-publication (Table 1) .
Discussion
Over a 10-year period, 12% (42/362) of clinical trials of neurodegenerative diseases registered on ClinicalTrials.gov were discontinued prematurely. Moreover, 28% (91/320) of completed trials remained unpublished after 5 years. In total, 12 442 patients contributed to these unpublished trials of neurodegenerative diseases. These figures are comparable to previously reported rates in other medical specialties [5, 6] .
Examining the factors that influence trial discontinuation and non-publication may identify ways of reducing research waste in the future. Two characteristics that influenced trial discontinuation were identified: number of patients and phase of trial. One possible reason for phase IV trials being prematurely discontinued would be to avoid ongoing costs for a treatment lacking efficacy or leading to adverse events. However, this was not supported by our results when the reasons for trial discontinuation were examined, although almost one-third of studies did not cite a reason at all.
A number of characteristics were identified that influenced trial non-publication: blinding status, number of centres, phase of trial and sponsor category. Single-blind and single-centre trials are generally considered less methodologically robust when assessing intervention efficacy and might therefore be less likely to be accepted for publication. In the same way, a phase II trial might be considered an intermediate step before a late phase study can be performed, making it less likely to be submitted for publication. A recent systematic review of trials into medical conditions similarly found that decreasing number of centres and decreasing phase of trial were positively associated with trial non-publication [4] . Our study found that industry-sponsored trials were significantly less likely to be published, confirming that neurodegenerative disease research is not immune to the influence of industry sponsorship on publication rates that has been observed in other medical conditions [4] [5] [6] . This might reflect the desire to protect intellectual property of early stage therapeutics; however, it might be to conceal negative results. Whilst recognizing the important role of industry in funding research into neurodegenerative diseases, our results reiterate the importance of creating a regulatory system in which publication of trial results is mandatory.
The strengths of this study are the large number of trials included from the largest trial registration database available and the significant efforts made to contact authors to ask about missing publications. Whilst other publicly available trial registration databases were not searched, it is known that two-thirds of all studies registered between 2005 and 2013 were on ClinicalTrials.gov [7] , meaning that a significant proportion of trials performed during the specified time period are likely to have been captured.
Potential limitations of the study include the exclusion of non-randomized trials, which might have led to an underestimation of non-publication rates. Restricting our search to ClinicalTrials.gov might also have led to an underestimation of discontinuation or non-publication rates because some smaller, singlecentre studies may only be registered in national trial registries. Our study design means that trials completed before 2010 but published after 2015 might have been missed. Furthermore, registration and publication patterns might have changed since the studied time period.
In summary, this is the first study to investigate non-dissemination bias in clinical trials of neurodegenerative diseases. It is imperative that greater efforts are made to improve the completion and publication of clinical trials of neurodegenerative diseases since 'hidden data' can impede scientific advancement by overestimating benefits and underestimating harm [8] , as well as wasting money and exposing research patients to unnecessary risk. Ongoing efforts include the 'Reduce Research Waste and Reward Diligence' (REWARD) campaign launched by The Lancet in 2015, which invites organizations involved in biomedical research to commit to increasing value and reducing waste [9] . Journals have been established specifically for the purpose of publishing statistically non-significant findings, making this reason for non-publication unjustifiable. Ultimately, researchers have an ethical responsibility to disseminate results from all trials, and the research community has a responsibility to facilitate and study this transfer of information [10] . This should include regulatory changes if necessary, as well as greater use of open-access publishing and mechanisms for sharing patient-level data [11] .
